Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Amplia receives R&D Tax Rebate
Key chemical form patents in Europe and Japan
Fourth partial response confirmed in ACCENT trial
ASX Briefs podcast | Interview with Dr Chris Burns
Three confirmed partial responses observed in Phase 2a ACCENT trial
JustStocks Feature Article and Video Interview with Amplia CEO Dr Chris Burns
Categories
Archive
Company News
Investor Newsletters
Videos
03 Jul 2024
Recruitment of first 26 patients of Phase 2A ACCENT Trial now complete
Read More
05 Jun 2024
Biotech Daily | Dr Boreham's Crucible: Amplia Therapeutics
Read More
16 Apr 2024
Entitlement Offer to raise $4.27m
Read More
13 Feb 2024
Proactive Interview with Dr Chris Burns
Read More
18 Jan 2024
FDA clearance of Amplia's IND for pancreatic cancer trial in US
Read More
17 Jan 2024
First patient dosed in phase 2a ACCENT trial
Read More
18 Dec 2023
Investor Newsletter - December 2023
Read More
04 Dec 2023
Approval from Korean regulator to initiate Phase 2 accent pancreatic cancer trial in Korea
Read More
21 Nov 2023
AUSBIZ | Interview with Dr Chris Burns
Read More
30 Oct 2023
Phase 1B of ACCENT Trial in Pancreatic Cancer Complete
Read More
20 Oct 2023
VIDEO | The Market Herald
Read More
09 Oct 2023
AACR Ovarian Cancer Conference Presentation
Read More
29 Sep 2023
Poster presentation at AACR Special Conference on Pancreatic Cancer
Read More
25 Sep 2023
Amplia appoints new CFO
Read More
02 Aug 2023
ACCENT Trial Recruitment Update
Read More
31 Jul 2023
Quarterly Activities and Cash Flow Report - 30 June 2023
Read More
20 Jul 2023
Investor Newsletter July 2023
Read More
19 Jul 2023
Dr Chris Burns to speak at Bio Connections Australia
Read More
21 Jun 2023
International Nonproprietary Name announced for AMP945
Read More
13 Jun 2023
Independent Non-Executive Director recognised in King’s Birthday Honours List
Read More
1
2